NCT01060124View on ClinicalTrials.gov

An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Cancer Participants With Inadequately Controlled Pain by Non-Narcotic Analgesics

PHASE4CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Pain; Cancer
Interventions
DRUG

Fentanyl D-trans

Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.

All Listed Sponsors
lead

Janssen Korea, Ltd., Korea

INDUSTRY

NCT01060124 - An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Cancer Participants With Inadequately Controlled Pain by Non-Narcotic Analgesics | Biotech Hunter | Biotech Hunter